Antibe Therapeutics Announces Administrative Items and Congratulates Dr. John Wallace on Publication in Nature Reviews

TORONTO--()--Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV:ATE) announced today the following:

Antibe wishes to congratulate its CSO, Dr. John Wallace, on the publication of a paper entitled “Hydrogen sulfide-based therapeutics: exploiting a unique but ubiquitous gasotransmitter” in the prestigious journal, Nature Reviews Drug Discovery. The paper, co-authored by Dr. Wallace and Dr. Rui Wang, written in the fall of 2014, will appear in the journal’s May 2015 edition. A copy of the paper is available on the Company’s website.

Antibe is pleased to announce that it has become eligible for the book-entry delivery and depository services of The Depository Trust Company (the "DTC") to facilitate electronic settlement and transfer of its common shares in the US. Securities approved for electronic clearance and settlement through the DTC are considered "DTC eligible." DTC eligibility enables Antibe’s stock to be traded by a wider selection of US brokerage firms, many of whom require DTC eligibility as a prerequisite for trading.

The Company announced that it has granted a previous officer 148,936 common shares in the Company at the April 30, 2015 closing market price of $0.235 per common share for a total value of $35,000. This grant has been made in exchange for the officer waiving a portion of the cash component of the officer’s severance.

Finally, Antibe announced that it has granted options to Hamza Thindal Capital Corporation (“HTCC”) in exchange for consulting services to be provided by HTCC under the terms of a consulting agreement. Under the terms of the agreement, HTCC will be granted 300,000 options. Such options will vest quarterly starting on the date of the grant, will be exercisable at a price of $0.235, and will expire May 5, 2018

About Antibe Therapeutics Inc.

Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer non-steroidal anti-inflammatory drug (NSAID) for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a safer analgesic for severe acute pain.

www.antibethera.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Important Note on Forward Looking Statements

Contacts

Antibe Therapeutics Inc.
Dan Legault, 416-473 4095
Chief Executive Officer
dan.legault@antibethera.com

Release Summary

Antibe Therapeutics Announces Administrative Items and Congratulates Dr. John Wallace on Publication in Nature Reviews

Contacts

Antibe Therapeutics Inc.
Dan Legault, 416-473 4095
Chief Executive Officer
dan.legault@antibethera.com